Aldo Maggioni to Risk Factors
This is a "connection" page, showing publications Aldo Maggioni has written about Risk Factors.
Connection Strength
0.242
-
[CoViD-19 and chronic diseases: current knowledge, future steps and the MaCroScopio project.] Recenti Prog Med. 2020 04; 111(4):198-201.
Score: 0.026
-
Use of lipid lowering drugs in patients at very high risk of cardiovascular events: An analysis on nearly 3,000,000 Italian subjects of the ARNO Observatory. Int J Cardiol. 2017 Nov 01; 246:62-67.
Score: 0.021
-
Drug-Drug Interactions and Prescription Appropriateness in Patients with COVID-19: A Retrospective Analysis from a Reference Hospital in Northern Italy. Drugs Aging. 2020 12; 37(12):925-933.
Score: 0.007
-
Pregnancy outcomes in women with cardiovascular disease: evolving trends over 10 years in the ESC Registry Of Pregnancy And Cardiac disease (ROPAC). Eur Heart J. 2019 12 14; 40(47):3848-3855.
Score: 0.006
-
Association between antithrombotic treatment and outcomes at 1-year follow-up in patients with atrial fibrillation: the EORP-AF General Long-Term Registry. Europace. 2019 07 01; 21(7):1013-1022.
Score: 0.006
-
Safety of Proton Pump Inhibitors Based on a Large, Multi-Year, Randomized Trial of Patients Receiving Rivaroxaban or Aspirin. Gastroenterology. 2019 09; 157(3):682-691.e2.
Score: 0.006
-
Major cardiac and vascular complications after transvenous lead extraction: acute outcome and predictive factors from the ESC-EHRA ELECTRa (European Lead Extraction ConTRolled) registry. Europace. 2019 May 01; 21(5):771-780.
Score: 0.006
-
Stroke Outcomes in the COMPASS Trial. Circulation. 2019 02 26; 139(9):1134-1145.
Score: 0.006
-
Lifestyle and impact on cardiovascular risk factor control in coronary patients across 27 countries: Results from the European Society of Cardiology ESC-EORP EUROASPIRE V registry. Eur J Prev Cardiol. 2019 05; 26(8):824-835.
Score: 0.006
-
Comparative Analysis of Long-Term Outcomes of Torasemide and Furosemide in Heart Failure Patients in Heart Failure Registries of the European Society of Cardiology. Cardiovasc Drugs Ther. 2019 02; 33(1):77-86.
Score: 0.006
-
Retinopathy, Neuropathy, and Subsequent Cardiovascular Events in Patients with Type 2 Diabetes and Acute Coronary Syndrome in the ELIXA: The Importance of Disease Duration. J Diabetes Res. 2018; 2018:1631263.
Score: 0.006
-
Association of metabolic syndrome with non-thromboembolic adverse cardiac outcomes in patients with atrial fibrillation. Eur Heart J. 2018 12 01; 39(45):4030-4039.
Score: 0.006
-
Factors associated with anticoagulation prescription in elderly patients with atrial fibrillation. Eur J Prev Cardiol. 2019 04; 26(6):660-663.
Score: 0.006
-
Changes to oral anticoagulant therapy and risk of death over a 3-year follow-up of a contemporary cohort of European patients with atrial fibrillation final report of the EURObservational Research Programme on Atrial Fibrillation (EORP-AF) pilot general registry. Int J Cardiol. 2018 Nov 15; 271:68-74.
Score: 0.006
-
Management and prognosis of atrial fibrillation in diabetic patients: an EORP-AF General Pilot Registry report. Eur Heart J Cardiovasc Pharmacother. 2018 07 01; 4(3):172-179.
Score: 0.006
-
Performance of Prognostic Risk Scores in Chronic Heart Failure Patients Enrolled in the European Society of Cardiology Heart Failure Long-Term Registry. JACC Heart Fail. 2018 06; 6(6):452-462.
Score: 0.006
-
Increased burden of comorbidities and risk of cardiovascular death in atrial fibrillation patients in Europe over ten years: A comparison between EORP-AF pilot and EHS-AF registries. Eur J Intern Med. 2018 09; 55:28-34.
Score: 0.006
-
Non-alcoholic fatty liver disease and increased risk of all-cause mortality in elderly patients admitted for acute heart failure. Int J Cardiol. 2018 Aug 15; 265:162-168.
Score: 0.006
-
Contemporary stroke prevention strategies in 11 096 European patients with atrial fibrillation: a report from the EURObservational Research Programme on Atrial Fibrillation (EORP-AF) Long-Term General Registry. Europace. 2018 05 01; 20(5):747-757.
Score: 0.006
-
Sudden Death After Hospitalization for Heart Failure With Reduced Ejection Fraction (from the EVEREST Trial). Am J Cardiol. 2018 07 15; 122(2):255-260.
Score: 0.006
-
Treatment with insulin is associated with worse outcome in patients with chronic heart failure and diabetes. Eur J Heart Fail. 2018 05; 20(5):888-895.
Score: 0.006
-
Statin utilization and lipid goal attainment in high or very-high cardiovascular risk patients: Insights from Italian general practice. Atherosclerosis. 2018 04; 271:120-127.
Score: 0.006
-
Overweight and obesity in patients with atrial fibrillation: Sex differences in 1-year outcomes in the EORP-AF General Pilot Registry. J Cardiovasc Electrophysiol. 2018 04; 29(4):566-572.
Score: 0.006
-
Regional Validation and Recalibration of Clinical Predictive Models for Patients With Acute Heart Failure. J Am Heart Assoc. 2017 Nov 18; 6(11).
Score: 0.006
-
Increases in Natriuretic Peptides Precede Heart Failure Hospitalization in Patients With a Recent Coronary Event and Type 2 Diabetes Mellitus. Circulation. 2017 10 17; 136(16):1560-1562.
Score: 0.006
-
Pre-discharge and early post-discharge troponin elevation among patients hospitalized for heart failure with reduced ejection fraction: findings from the ASTRONAUT trial. Eur J Heart Fail. 2018 02; 20(2):281-291.
Score: 0.006
-
Use of statins and adverse outcomes in patients with atrial fibrillation: An analysis from the EURObservational Research Programme Atrial Fibrillation (EORP-AF) general registry pilot phase. Int J Cardiol. 2017 Dec 01; 248:166-172.
Score: 0.005
-
Heart failure with reduced ejection fraction. Nat Rev Dis Primers. 2017 Aug 24; 3:17058.
Score: 0.005
-
Prognostic Impact of Diabetes and Prediabetes on Survival Outcomes in Patients With Chronic Heart Failure: A Post-Hoc Analysis of the GISSI-HF (Gruppo Italiano per lo Studio della Sopravvivenza nella Insufficienza Cardiaca-Heart Failure) Trial. J Am Heart Assoc. 2017 Jul 05; 6(7).
Score: 0.005
-
Seattle Heart Failure and Proportional Risk Models Predict Benefit From Implantable Cardioverter-Defibrillators. J Am Coll Cardiol. 2017 May 30; 69(21):2606-2618.
Score: 0.005
-
Role of B-Type Natriuretic Peptide and N-Terminal Prohormone BNP as Predictors of Cardiovascular Morbidity and Mortality in Patients With a Recent Coronary Event and Type 2 Diabetes Mellitus. J Am Heart Assoc. 2017 May 29; 6(6).
Score: 0.005
-
Self-reported physical activity and major adverse events in patients with atrial fibrillation: a report from the EURObservational Research Programme Pilot Survey on Atrial Fibrillation (EORP-AF) General Registry. Europace. 2017 Apr 01; 19(4):535-543.
Score: 0.005
-
Anemia at Hospital Admission and Its Relation to Outcomes in Patients With Heart Failure (from the Polish Cohort of 2 European Society of Cardiology Heart Failure Registries). Am J Cardiol. 2017 06 15; 119(12):2021-2029.
Score: 0.005
-
Association Between Diabetes and 1-Year Adverse Clinical Outcomes in a Multinational Cohort of Ambulatory Patients With Chronic Heart Failure: Results From the ESC-HFA Heart Failure Long-Term Registry. Diabetes Care. 2017 05; 40(5):671-678.
Score: 0.005
-
Baseline characteristics of patients enrolled in the Exenatide Study of Cardiovascular Event Lowering (EXSCEL). Am Heart J. 2017 May; 187:1-9.
Score: 0.005
-
Regular wine consumption in chronic heart failure: impact on outcomes, quality of life, and circulating biomarkers. Circ Heart Fail. 2015 May; 8(3):428-37.
Score: 0.005